Form 4: RA Capital Management Increases Stake in Cidara Therapeutics Through Stock and Warrant Acquisition

RA Capital Management and related entities have increased their holdings in Cidara Therapeutics through the acquisition of common stock and pre-funded warrants.

Summary

• RA Capital Management, L.P., along with related entities, has reported an increase in their beneficial ownership of Cidara Therapeutics, Inc. common stock.
• The transactions occurred on November 26, 2024, and involved the acquisition of 389,716 shares of common stock at a price of $14.912 per share.
• Additionally, RA Capital acquired 1,286,786 pre-funded warrants, each exercisable for one share of common stock at a price of $0.0001.
• Following these transactions, RA Capital and related entities now beneficially own 1,092,796 shares of common stock and 1,286,786 pre-funded warrants.
• The pre-funded warrants are immediately exercisable but are subject to a 9.99% ownership cap.

Sentiment

Score: 7

Explanation: The document indicates a positive move by a major investor, suggesting confidence in the company's future, but it is a routine filing and does not contain any specific forward looking statements.

Positives

• RA Capital Management's increased investment signals confidence in Cidara Therapeutics.
• The acquisition of pre-funded warrants provides potential for further ownership increase in the future.

Risks

• The pre-funded warrants are subject to a 9.99% ownership cap, which may limit RA Capital's ability to fully exercise them.
• The document does not provide any information about the future performance of the company.

Management Comments

• Dr. Peter Kolchinsky and Mr. Rajeev Shah, managing members of RA Capital Management GP, LLC, disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
• Dr. Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors.

Industry Context

This filing indicates a significant investment by a major healthcare-focused investment firm, which could signal positive sentiment towards Cidara Therapeutics within the biotech industry.

Comparison to Industry Standards

• RA Capital Management is a well-known healthcare investment firm, and their increased stake in Cidara Therapeutics is a notable event.
• Similar investments by institutional investors are common in the biotech sector, often indicating confidence in a company's prospects.
• The acquisition of pre-funded warrants is a common mechanism for investors to increase their potential ownership in a company.

Stakeholder Impact

• The increased investment by RA Capital may positively impact shareholder confidence.
• The transaction does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

RA Capital Management, Cidara Therapeutics, Beneficial Ownership, Pre-Funded Warrants, Common Stock, Investment, Acquisition